Combination therapy with ABT-737 extends survival. Safe regimens were established from previously published data12,18,19 and our own dose-finding studies (data not shown). Nonirradiated C57BL/6 recipients were transplanted with 3 independent bim+/+myc/bcl-2 lymphomas (nos. 9, 12, 16) (3 × 106 tumor cells per mouse) 4 days prior to commencement of treatment. ABT-737 was administered intraperitoneally at 75 mg/kg per day for 10 days (bar), starting on day 1; cyclophosphamide (CTX; 50 mg/kg) intraperitoneally on days 3, 8; bortezomib (0.5 mg/kg) intraperitoneally on days 1, 3, 5, 8, 10; purvalanol A (20 mg/kg) intraperitoneally on days 1, 3, 5, 8, 10, alone or in combination with ABT-737, with at least 6 mice per indicated treatment arm (supplemental Tables 1-2). With tumor 16, all mice treated with ABT-737 alone remained healthy until the experiment was terminated at day 150 (supplemental Table 2 and data not shown; controls treated with vehicle were all dead by day 35).
